{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:54:16Z","timestamp":1780340056599,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00520-023-07579-9","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T07:04:00Z","timestamp":1678172640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nursing care and management of adverse events for patients with BRAFV600E-mutant metastatic colorectal cancer receiving encorafenib in combination with cetuximab: a review"],"prefix":"10.1007","volume":"31","author":[{"given":"Matthew","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Tobback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Karuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Fern\u00e1ndez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"7579_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387","journal-title":"Eur J Cancer"},{"key":"7579_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JGO.19.00367","volume":"6","author":"EG Chiorean","year":"2020","unstructured":"Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru A-E, Grover S, Lohar PV, Odhiambo A (2020) Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol 6:414\u2013438","journal-title":"JCO Glob Oncol"},{"key":"7579_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jbo.2018.09.009","volume":"13","author":"TD Christensen","year":"2018","unstructured":"Christensen TD, Jensen SG, Larsen FO, Nielsen DL (2018) Systematic review: incidence, risk factors, survival and treatment of bone metastases from colorectal cancer. J Bone Oncol 13:97\u2013105","journal-title":"J Bone Oncol"},{"key":"7579_CR4","doi-asserted-by":"publisher","first-page":"7407190","DOI":"10.1155\/2019\/7407190","volume":"2019","author":"E Pretzsch","year":"2019","unstructured":"Pretzsch E, B\u00f6sch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J, Angele M (2019) Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol 2019:7407190","journal-title":"J Oncol"},{"key":"7579_CR5","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386\u20131422","journal-title":"Ann Oncol"},{"key":"7579_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Targeted Ther 5:1\u201330","journal-title":"Signal Transduct Targeted Ther"},{"key":"7579_CR7","first-page":"581","volume":"7","author":"D Dinu","year":"2014","unstructured":"Dinu D, Dobre M, Panaitescu E, B\u00eerl\u0103 R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S, Ardeleanu C (2014) Prognostic significance of KRAS gene mutations in colorectal cancer-preliminary study. J Med Life 7:581","journal-title":"J Med Life"},{"key":"7579_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS (2021) Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated Survival results and subgroup analyses from the BEACON study. J Clin Oncol 39:273\u2013284","journal-title":"J Clin Oncol"},{"key":"7579_CR9","unstructured":"ESMO (2020) ESMO pocket guidelines: Lower gastrointestinal cancer. Available at: http:\/\/interactiveguidelines.esmo.org\/esmo-web-app\/home\/gl_home.php?GL=45. Accessed September 2021"},{"key":"7579_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","volume":"121","author":"J Taieb","year":"2019","unstructured":"Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A (2019) Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer 121:434\u2013442","journal-title":"Br J Cancer"},{"key":"7579_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9250757","volume":"2018","author":"CE Bond","year":"2018","unstructured":"Bond CE, Whitehall VL (2018) How the BRAF V600E mutation defines a distinct subgroup of colorectal cancer: molecular and clinical implications. Gastroenterol Res Pract 2018:925075","journal-title":"Gastroenterol Res Pract"},{"key":"7579_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JH, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 8:428\u2013443","journal-title":"Cancer Discov"},{"key":"7579_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100795","volume":"13","author":"G Roviello","year":"2020","unstructured":"Roviello G, D'Angelo A, Petrioli R, Roviello F, Cianchi F, Nobili S, Mini E, Lavacchi D (2020) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. Transl Oncol 13:100795","journal-title":"Transl Oncol"},{"key":"7579_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE (2012) EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227\u2013235","journal-title":"Cancer Discov"},{"key":"7579_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","volume":"6","author":"DS Hong","year":"2016","unstructured":"Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R et al (2016) Phase IB Study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov 6:1352\u20131365","journal-title":"Cancer Discov"},{"key":"7579_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100\u2013103","journal-title":"Nature"},{"key":"7579_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","volume":"37","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle P-J, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T (2019) Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E\u2013mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON Colorectal Cancer Study. J Clin Oncol 37:1460","journal-title":"J Clin Oncol"},{"key":"7579_CR18","unstructured":"FDA (2020) FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation. Accessed September 2021"},{"key":"7579_CR19","unstructured":"Pierre Fabre Medicament (2020) Pierre Fabre receives European approval for BRAFTOVI\u00ae (encorafenib). Available at: \u00a0https:\/\/www.pierre-fabre.com\/en\/press_release\/pierre-fabre-receives-european-approval-for-braftovir-encorafenib. Accessed September 2021"},{"key":"7579_CR20","unstructured":"Pierre Fabre Medicament (2020) BRAFTOVI\u00ae (encorafenib). Summary of product characteristics Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/braftovi-epar-product-information_en.pdf"},{"key":"7579_CR21","unstructured":"Pfizer (2020) Taking BRAFTOVI + MEKTOVI. Available at:\u00a0https:\/\/www.braftovimektovi.com\/taking-braftovi-mektovi\/"},{"key":"7579_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11606-014-3101-9","volume":"30","author":"JE Aikens","year":"2015","unstructured":"Aikens JE, Trivedi R, Aron DC, Piette JD (2015) Integrating support persons into diabetes telemonitoring to improve self-management and medication adherence. J Gen Intern Med 30:319\u2013326","journal-title":"J Gen Intern Med"},{"key":"7579_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/pds.4988","volume":"29","author":"B Riegel","year":"2020","unstructured":"Riegel B, Stephens-Shields A, Jaskowiak-Barr A, Daus M, Kimmel SE (2020) A behavioral economics-based telehealth intervention to improve aspirin adherence following hospitalization for acute coronary syndrome. Pharmacoepidemiology and drug safety 29:513\u2013517","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"7579_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1037\/a0036322","volume":"59","author":"AP Turner","year":"2014","unstructured":"Turner AP, Sloan AP, Kivlahan DR, Haselkorn JK (2014) Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis. Rehabil Psychol 59:136","journal-title":"Rehabil Psychol"},{"key":"7579_CR25","unstructured":"Hergert J (2021) Biweekly Cetuximab offers a convenient dosing option in mCRC. Available at:  https:\/\/www.onclive.com\/view\/biweekly-cetuximab-offers-a-convenient-dosing-option-in-mcrc. Accessed September 2021"},{"key":"7579_CR26","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.21873\/anticanres.14333","volume":"40","author":"A Matsuda","year":"2020","unstructured":"Matsuda A, Yamada T, Jmjittrong S, Shinji S, Ohta R, Sonoda H, Kamonvarapitak T, Sekiguchi K, Miyashita M, Suzuki H, Yoshida H (2020) Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis. Anticancer Res 40:3469\u20133476","journal-title":"Anticancer Res"},{"key":"7579_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.20517\/2572-8180.2016.02","volume":"1","author":"J Zekri","year":"2016","unstructured":"Zekri J, Farag K, Al-Saadi R, Ashour M, Haggag R (2016) Safety and efficacy of biweekly cetuximab based chemotherapy for patients with metastatic colorectal cancer. J Unexplored Med Data 1:15\u201320","journal-title":"J Unexplored Med Data"},{"key":"7579_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.critrevonc.2017.03.032","volume":"114","author":"R-D Hofheinz","year":"2017","unstructured":"Hofheinz R-D, Segaert S, Safont MJ, Demonty G, Prenen H (2017) Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical Reviews in Oncology\/Hematology 114:102\u2013113","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"7579_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","volume":"78","author":"JN Sanchez","year":"2018","unstructured":"Sanchez JN, Wang T, Cohen MS (2018) BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs 78:549\u2013566","journal-title":"Drugs"},{"key":"7579_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7:122\u2013136","journal-title":"Ther Adv Med Oncol"},{"key":"7579_CR31","first-page":"29","volume":"3","author":"E Livingstone","year":"2014","unstructured":"Livingstone E, Zimmer L, Vaubel J, Schadendorf D (2014) BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol 3:29\u201329","journal-title":"Chin Clin Oncol"},{"key":"7579_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CMR.0000000000000599","volume":"29","author":"AG Mackin","year":"2019","unstructured":"Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG (2019) Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res 29:522\u2013526","journal-title":"Melanoma Res"},{"key":"7579_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4:e000491","journal-title":"ESMO Open"},{"key":"7579_CR34","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, Totzeck M (2019) Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Network Open 2:e198890\u2013e198890","journal-title":"JAMA Network Open"},{"key":"7579_CR35","unstructured":"Merck (2020) ERBITUX\u00ae (cetuximab) Summary of product characteristics available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erbitux"},{"key":"7579_CR36","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1038\/onc.2017.189","volume":"36","author":"W Damsky","year":"2017","unstructured":"Damsky W, Bosenberg M (2017) Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene 36:5771\u20135792","journal-title":"Oncogene"},{"issue":"491-499","key":"7579_CR37","volume":"73","author":"MC Mochel","year":"2015","unstructured":"Mochel MC, Hammond MR, Frederick DT, Alora-Palli MB, Piris A, Flaherty KT, Hoang MP (2015) Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: a study of 19 lesions from 10 patients. J Am Acad Dermatol 73(491-499):e492","journal-title":"J Am Acad Dermatol"},{"key":"7579_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamadermatol.2013.21","volume":"149","author":"S Dalle","year":"2013","unstructured":"Dalle S, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, Rosen A, Marghoob AA, Busam KJ, Depaepe L (2013) Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol 149:488\u2013490","journal-title":"JAMA Dermatol"},{"key":"7579_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2340\/00015555-1813","volume":"94","author":"D G\u00f6ppner","year":"2014","unstructured":"G\u00f6ppner D, M\u00fcller J, Kr\u00fcger S, Franke I, Gollnick H, Quist SR (2014) High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib. Acta Derm Venereol 94:517\u2013520","journal-title":"Acta Derm Venereol"},{"key":"7579_CR40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375","journal-title":"J Clin Oncol"},{"key":"7579_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1188\/17.CJON.699-709","volume":"21","author":"KM Rubin","year":"2017","unstructured":"Rubin KM (2017) MAPK pathway-targeted therapies: care and management of unique toxicities in patients with advanced melanoma. Clin J Oncol Nurs 21:699\u2013709","journal-title":"Clin J Oncol Nurs"},{"key":"7579_CR42","first-page":"319","volume":"4","author":"C Urban","year":"2013","unstructured":"Urban C, Anadkat MJ (2013) A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. J Gastrointest Oncol 4:319","journal-title":"J Gastrointest Oncol"},{"key":"7579_CR43","first-page":"46","volume":"39","author":"J Tabernero","year":"2020","unstructured":"Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T (2020) Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (The BEACON CRC Study). Hemoglobin 39:46","journal-title":"Hemoglobin"},{"key":"7579_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000277656","volume":"33","author":"JC Hassel","year":"2010","unstructured":"Hassel JC, Kripp M, Al-Batran S, Hofheinz R-D (2010) Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 33:94\u201398","journal-title":"Onkologie"},{"key":"7579_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31\u201339","journal-title":"Am J Clin Dermatol"},{"key":"7579_CR46","unstructured":"Cancer Net (2019) Skin conditions. Available at:  https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/skin-conditions. Accessed August 2020"},{"key":"7579_CR47","unstructured":"Dermatology AAo (2019) Sunscreen FAQs. Available at:  https:\/\/www.aad.org\/public\/everyday-care\/sun-protection\/sunscreen-patients\/sunscreen-faqs. Accessed November 2021"},{"key":"7579_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2478\/raon-2013-0014","volume":"47","author":"J Ocvirk","year":"2013","unstructured":"Ocvirk J, Heeger S, McCloud P, Hofheinz R-D (2013) A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 47:166","journal-title":"Radiol Oncol"},{"key":"7579_CR49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00520-009-0656-9","volume":"18","author":"F Romito","year":"2010","unstructured":"Romito F, Giuliani F, Cormio C, Tulipani C, Mattioli V, Colucci G (2010) Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 18:329\u2013334","journal-title":"Support Care Cancer"},{"key":"7579_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/CCO.0b013e3283474063","volume":"23","author":"PA Wu","year":"2011","unstructured":"Wu PA, Balagula Y, Lacouture ME, Anadkat MJ (2011) Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 23:343\u2013351","journal-title":"Curr Opin Oncol"},{"key":"7579_CR51","unstructured":"Cancer Net (2018) Muscle aches. Available at:  https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/muscle-aches. Accessed August 2020"},{"key":"7579_CR52","first-page":"27","volume":"16","author":"B Zhang","year":"2018","unstructured":"Zhang B, Fang C, Deng D, Xia L (2018) Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett 16:27\u201333","journal-title":"Oncol Lett"},{"key":"7579_CR53","unstructured":"Peniket A, Maouche N (2015) Guidelines for the management of hypomagnesaemia in adult clinical haematology patients. Available at:  http:\/\/nssg.oxford-haematology.org.uk\/oxford\/clinical-care\/H-95-guidelines-for-management-of-hypomagnesaemia-in-adult-clinical-haematology.pdf. Accessed September 2021"},{"key":"7579_CR54","unstructured":"NCI (2017) Common terminology criteria for adverse events (CTCAE), version 5.0 Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"7579_CR55","unstructured":"Preece D (2020) How is acute hypomagnesaemia treated in adults? Available at:  https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2016\/01\/UKMI_QA_How_is_acute_hypomagnesaemia_treated_in_adults_update_Nov_2020.pdf. Accessed September 2021"},{"key":"7579_CR56","unstructured":"Cancer Net (2020) Fatigue. Available at:  https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/fatigue. Accessed August 2020"},{"key":"7579_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.apnr.2013.08.004","volume":"26","author":"S Strupeit","year":"2013","unstructured":"Strupeit S, Bu\u00df A, Dassen T (2013) Effectiveness of nurse-delivered patient education interventions on quality of life in outpatients: a systematic review. Appl Nurs Res 26:232\u2013238","journal-title":"Appl Nurs Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07579-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:47:00Z","timestamp":1744210020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07579-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7579"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07579-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not report a scientific study; therefore, no ethics approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This manuscript does not report a scientific study; therefore, no informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that their patients provided informed consent for publication of the patient images in Fig. .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mathew Fowler (corresponding author) was an advisory board member for Vygon and received honoraria from Sanofi. Helene Tobback, Alice Karuri and Paz Fernandez\u2013Ortega have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}